Prosecution Insights
Prosecution Insights
25 pending office actions • 22 art units • 24 examiners • 0 of 25 (0%) have an AI response strategy ready • 65 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 25 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 25 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 16 (64%) |
| §102 only | 3 (12%) |
| §112 only | 2 (8%) |
| No statute on record | 4 (16%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POLIAKOVA-GEORGAN, EKATERINA | 2 | 64.6% | +17.0% |
| BEISNER, WILLIAM H | 1 | 61.6% | +29.4% |
| XU, XIAOYUN | 1 | 59.6% | +32.3% |
| MIDDLETON, DANAYA L | 1 | 43.5% | +53.4% |
| SMALE, AVERY E | 1 | 72.9% | +22.2% |
| NGUYEN, QUANG | 1 | 38.2% | +52.8% |
| HAVLIN, ROBERT H | 1 | 52.3% | +27.2% |
| SHIBUYA, MARK LANCE | 1 | 32.3% | +24.9% |
| PARISI, JESSICA DANIELLE | 1 | 79.8% | +28.0% |
| KOSAR, ANDREW D | 1 | 42.1% | +31.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18236462 | METHODS FOR TREATING RECEPTOR-INTERACTING PROTEIN KINASE 1-MEDIATED DISEASES | HAVLIN, ROBERT H | 138d overdue |
| 18304519 | Compositions and Methods for Treating Spinal Muscular Atrophy | POLIAKOVA-GEORGAN, EKATERINA | 105d overdue |
| 18317772 | METHODS OF TREATING METACHROMATIC LEUKODYSTROPHY | SHIBUYA, MARK LANCE | 37d overdue |
| 19347877 | DEVICES FOR CELL LYSIS AND METHODS OF USE THEREOF | BEISNER, WILLIAM H | 17d overdue |
| 18628338 | FLUID GUIDE SYSTEM USABLE FOR DRUG HANDLING, E.G. FOR RECONSTITUTION, CORRESPONDING MEDICAL DEVICE, METHOD AND COMPUTER RELATED ITEMS | SMALE, AVERY E | 17d overdue |
| 18299640 | USE OF AN IRAK4 MODULATOR FOR GENE THERAPY | KOSAR, ANDREW D | 8d |
| 18644528 | HUMANIZED ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF | MIDDLETON, DANAYA L | 13d |
| 19013836 | METHODS FOR DETECTING AAV | XU, XIAOYUN | 28d |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1637 | 2 |
| 1675 | 2 |
| 1799 | 1 |
| 1797 | 1 |
| 1674 | 1 |
| 3783 | 1 |
| 1626 | 1 |
| 1684 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19347877 | DEVICES FOR CELL LYSIS AND METHODS OF USE THEREOF | BEISNER, WILLIAM H | 1799 | §103 | Non-Final OA | 17d overdue | Pending | Oct 02, 2025 |
| 19013836 | METHODS FOR DETECTING AAV | XU, XIAOYUN | 1797 | §103 | Final Rejection | 28d | Pending | Jan 08, 2025 |
| 18644528 | HUMANIZED ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF | MIDDLETON, DANAYA L | 1674 | §112 | Non-Final OA | 13d | Pending | Apr 24, 2024 |
| 18628338 | FLUID GUIDE SYSTEM USABLE FOR DRUG HANDLING, E.G. FOR RECONSTITUTION, CORRESPONDING MEDICAL DEVICE, METHOD AND COMPUTER RELATED ITEMS | SMALE, AVERY E | 3783 | §103 | Final Rejection | 17d overdue | Pending | Apr 05, 2024 |
| 18407298 | RECOMBINANT AAV VECTORS EXPRESSING OSTEOPROTECTIVE GENES, INCLUDING HAS2 AND LUBRICIN, USEFUL IN THE TREATMENT OF OSTEOARTHRITIS AND RELATED JOINT CONDITIONS IN MAMMALS | NGUYEN, QUANG | 1631 | §103 | Non-Final OA | 86d | Pending | Jan 08, 2024 |
| 18236462 | METHODS FOR TREATING RECEPTOR-INTERACTING PROTEIN KINASE 1-MEDIATED DISEASES | HAVLIN, ROBERT H | 1626 | §102 | Non-Final OA | 138d overdue | Pending | Aug 22, 2023 |
| 18317772 | METHODS OF TREATING METACHROMATIC LEUKODYSTROPHY | SHIBUYA, MARK LANCE | 1631 | Other | Non-Final OA | 37d overdue | Pending | May 15, 2023 |
| 18315316 | FLOW CYTOMETRY ATTENUATED REPORTER EXPRESSION (FLARE) MULTIPLE REPORTER SYSTEM AND METHODS OF USE THEREOF | PARISI, JESSICA DANIELLE | 1684 | §103 | Non-Final OA | 46d | Pending | May 10, 2023 |
| 18304519 | Compositions and Methods for Treating Spinal Muscular Atrophy | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Other | Non-Final OA | 105d overdue | Pending | Apr 21, 2023 |
| 18299640 | USE OF AN IRAK4 MODULATOR FOR GENE THERAPY | KOSAR, ANDREW D | 1625 | §103 | Non-Final OA | 8d | Pending | Apr 12, 2023 |
| 18296283 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | BRETZ, COREY LANE | 1635 | Other | Non-Final OA | 56d | Pending | Apr 05, 2023 |
| 18025847 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | VAJDA, KRISTIN ANN | 1622 | §102 | Non-Final OA | 36d | Pending | Mar 10, 2023 |
| 18007433 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | SZNAIDMAN, MARCOS L | 1628 | §103 | Non-Final OA | 37d overdue | Pending | Jan 30, 2023 |
| 18051468 | TREATMENT OF OSTEOGENESIS IMPERFECTA | DUFFY, PATRICIA ANN | 1645 | §103 | Non-Final OA | 2d overdue | Pending | Oct 31, 2022 |
| 18045995 | FGFR3 ANTIBODIES AND METHODS OF USE | ALLEN, MARIANNE P | 1647 | §112 | Non-Final OA | 26d | Pending | Oct 12, 2022 |
| 17878884 | METHODS AND COMPOSITIONS FOR TREATING A BLEEDING EVENT IN A SUBJECT HAVING HEMOPHILIA | WHITEMAN, BRIAN A | 1636 | §103 | Final Rejection | 89d overdue | Pending | Aug 01, 2022 |
| 17843812 | ANTI-TGF-BETA ANTIBODY FORMULATIONS AND THEIR USE | BERHANE, SELAM | 1675 | §103 | Non-Final OA | 27d | Pending | Jun 17, 2022 |
| 17775446 | BIPARATOPIC CD73 ANTIBODIES | AEDER, SEAN E | 1642 | §103 | Final Rejection | 22d | Pending | May 09, 2022 |
| 17721003 | METHODS OF PERFUSION CULTURING A MAMMALIAN CELL | LEVIN, JOEL D | 1633 | §103 | Non-Final OA | 74d overdue | Pending | Apr 14, 2022 |
| 17403592 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES | LEE, HOI YAN NMN | 1693 | §103 | Final Rejection | 21d | Pending | Aug 16, 2021 |
| 17428505 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | PIHONAK, SARAH | 1627 | §103 | Final Rejection | 9d | Pending | Aug 04, 2021 |
| 17375785 | METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER | POLIAKOVA-GEORGAN, EKATERINA | 1637 | Other | Final Rejection | 54d | Pending | Jul 14, 2021 |
| 16807102 | METHODS FOR TREATING PROTEINOPATHIES | RODRIGUEZ-GARCIA, VALERIE | 1621 | §103 | Non-Final OA | 15d overdue | Pending | Mar 02, 2020 |
| 16088031 | BIOMARKERS OF PROTEOPATHIES AND USES THEREOF | FONTAINHAS, AURORA M | 1675 | §103 | Final Rejection | 35d | Pending | Sep 24, 2018 |
| 14004377 | PEGYLATED APELIN AND USES THEREOF | KOMATSU, LI N | 1658 | §102 | Non-Final OA | 44d overdue | Pending | Feb 10, 2014 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial